AMWC 2026: Galderma Showcases Category‑leading Innovation with a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies 

Galderma will present nine abstracts at the Aesthetic & Anti-Ageing Medicine (AMWC) World Congress 2026 in Monaco, showcasing and innovating robust scientific data across its aesthetics portfolio, highlighting three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions expanding the benefits of Sculptra, Relfydess, and the Restylane range. 

This trend‑led approach to innovation demonstrates Galderma's commitment to addressing emerging needs, such as menopause‑related skin changes, the growing interest in regenerative treatments, and the rising demand for body injectables. 

According to Towards Healthcare, the Poly-l-lactic acid filler Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.05 billion in 2026 to approximately USD 5.16 billion by 2035, representing a compound annual growth rate (CAGR) of 10.8% from 2026 to 2035. Growth is driven by the increasing demand for aesthetic procedures, leading to higher demand for fillers that offer non-surgical options for volume restoration and wrinkle reduction. Manufacturers are exploring eco-friendly production methods and sustainable sourcing of raw materials to meet the growing demand for environmentally responsible products. 

Galderma empowers clinicians with evidence-based guidance for managing increasingly complex patient profiles. 

Galderma will share insights into complex patient profiles, including findings from a global survey of over 4,300 women across five continents linking menopause to several skin changes, such as wrinkles, loss of firmness, dryness, and dull skin, and the growing relevance of aesthetic treatments in addressing these concerns. 

Focusing on menopause and addressing medication-driven weight loss on the body, this session will explore the clinical principles behind Galderma’s holistic treatment philosophy, examining how skin quality interventions can be integrated for personalised, high-impact results. This will encourage physicians to rethink treatment planning to respond to these increasing patient needs and explore the key trends shaping the aesthetics industry. 

About Galderma 

Galderma is a pure-play dermatology category leader, present in approximately 90 countries. It delivers an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. 

It is dedicated and passionate to the human body’s largest organ, the skin, meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals.  

A recent report by Towards Healthcare highlights that the Poly-l-lactic acid filler Market is witnessing growth, due to the driven by the increasing demand for minimally invasive cosmetic procedures and the ageing population. It focuses on technological advancements and product innovations to enhance market growth, followed by cosmetic surgery centres/dermatology clinics. 

The North America region is currently the largest market share holder in the Poly-l-lactic acid filler market. The U.S. Poly-l-lactic acid filler market is experiencing steady growth, driven by the increasing demand for non-invasive aesthetic treatments, particularly in facial rejuvenation and volumization. 

The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, fueled by rising disposable incomes, growing awareness of aesthetic treatments, and an expanding medical tourism industry.